QNRX Latest Press Releases

-- November 6, 2026 --

Quoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome Globe Newswire 8:30 AM

-- November 5, 2026 --

Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results Globe Newswire 8:30 AM

-- October 29, 2026 --

Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026 Globe Newswire 8:30 AM

-- October 20, 2026 --

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy Globe Newswire 6:30 AM

-- October 14, 2026 --

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome Globe Newswire 6:30 AM

-- October 6, 2026 --

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy Globe Newswire 6:30 AM

-- September 22, 2026 --

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome Globe Newswire 8:30 AM

-- September 10, 2026 --

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU Globe Newswire 8:30 AM

-- September 8, 2026 --

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome Globe Newswire 2:12 PM

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome Globe Newswire 8:30 AM

-- August 28, 2026 --

Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome Globe Newswire 6:00 AM

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million Globe Newswire 6:00 AM

-- August 14, 2026 --

Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results Globe Newswire 8:30 AM

-- August 7, 2026 --

Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 Globe Newswire 8:30 AM

-- July 9, 2026 --

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome Globe Newswire 8:30 AM

-- June 30, 2026 --

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome Globe Newswire 8:30 AM

-- June 23, 2026 --

Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI as the Proposed Brand Name for QRX003 for Netherton Syndrome Globe Newswire 8:30 AM

-- June 18, 2026 --

Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003 Globe Newswire 8:30 AM

-- June 16, 2026 --

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program Globe Newswire 8:30 AM

Market Data Delayed 15 Minutes